Then, the therapeutic efficacy of the CpG-CCNPs was also examined in B16-F10 tumor-bearing mice, and the results revealed that subcutaneous injection of the CpG-CCNPs combined with an intraperitoneal injection of anti-CTLA-4 and anti-PD-1 could inhibit tumor growth and prolong the survival time than other treatments. Here, CTLA4 is linked to neoplasm.